| 0.5828 0.033 (5.96%) | 08-21 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.71  |
1-year : | 0.77 |
| Resists | First : | 0.61 |
Second : | 0.66 |
| Pivot price | 0.57 |
|||
| Supports | First : | 0.52 | Second : | 0.44 |
| MAs | MA(5) : | 0.55 |
MA(20) : | 0.57 |
| MA(100) : | 0.72 |
MA(250) : | 0.87 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 31.2 |
D(3) : | 22.4 |
| RSI | RSI(14): 47.8 |
|||
| 52-week | High : | 2.03 | Low : | 0.42 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BFRG ] has closed below upper band by 46.1%. Bollinger Bands are 75.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 69 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.59 - 0.59 | 0.59 - 0.6 |
| Low: | 0.55 - 0.56 | 0.56 - 0.56 |
| Close: | 0.58 - 0.58 | 0.58 - 0.59 |
BullFrog AI Holdings, Inc., along with its affiliated entities, functions as an advanced digital biopharmaceutical firm. Its core mission involves harnessing artificial intelligence and machine learning (AI/ML) to process and interpret extensive medical and healthcare datasets specifically within the United States. A central offering is bfLEAP, a proprietary AI/ML platform meticulously crafted for the thorough examination of both preclinical and clinical research data. The company has also secured critical intellectual property through licensing agreements. One such accord, with George Washington University, provides rights to utilize siRNA targeting Beta2-spectrin. This technology is being investigated for its therapeutic potential across a spectrum of human conditions, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH). Additionally, a partnership with Johns Hopkins University grants access to a distinct Mebendazole formulation, developed for the treatment of various human cancers or neoplastic diseases. Founded in 2017, BullFrog AI Holdings, Inc. operates from its headquarters in Gaithersburg, Maryland.
Fri, 21 Aug 2026
BullFrog AI Granted Extended Nasdaq Compliance Period - The Globe and Mail
Fri, 14 Aug 2026
BullFrog AI Holdings (BFRG) posts Q2 2026 loss, flags going concern and Nasdaq risks - Stock Titan
Sun, 05 Apr 2026
Bullfrog AI Holdings’ Strategic Moves Signal Market Recovery - StocksToTrade
Wed, 01 Apr 2026
BullFrog AI Holdings regains Nasdaq equity compliance after $3.45M in equity raises - TradingView
Mon, 30 Mar 2026
A top-5 drugmaker taps BullFrog AI to hunt depression targets - Stock Titan
Wed, 14 Jan 2026
Bullfrog AI Holdings, Inc. Common Stock (NASDAQ: BFRG) Stock Price, News & Analysis - Kalkine
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 0 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 1.611e+007 (%) |
| Held by Institutions | 13.1 (%) |
| Shares Short | 399 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -6.15e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -5 % |
| Return on Assets (ttm) | 273.5 % |
| Return on Equity (ttm) | -80 % |
| Qtrly Rev. Growth | 116670 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -257.81 |
| EBITDA (p.s.) | 30831 |
| Qtrly Earnings Growth | -0.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | -6.08 |
| Dividend | 0 |
| Forward Dividend | 120260 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|